SecBot SecBot

CRDF

Cardiff Oncology, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001213037 Biotech & Drug Discovery
$0.8000 −0.11 (−12.09%)
Oct 26 4:00 PM ET · prev $0.9100
Market cap
$72.2M
Micro cap
Consensus
Buy
67% Buy or better · 12 analysts
Median target
$6.75
+744% · range $1.20–12.00
Next earnings
Oct 29
in 2 days · EPS est. −$0.13
1 year
−65.1%
from $2.29 · Oct 27
30 days
−33.3%
from $1.20
52-week range
$0.8000–3.21
at the low
Avg volume 20D
448.4K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$1.1M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 2 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Oct 29, 2026
Strongest BULLISH Cardiff Oncology and Nerviano Medical Sciences settled their patent inventorship litigation and amended…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.1M at an average $1.44. No open-market sales. Price is 44% below their cost.

  • InstitutionsMIXED

    Q2 2026: 15 added (0 new), 16 trimmed or exited.

  • AnalystsBULLISH

    8 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.168 → −$0.130 over 90 days. 4 up, 0 down in 30 days.

  • TrendDOWNTREND

    26% below its 50-day average. New closing low $0.8000 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.NEAR_EXIT972,873$1.3M
GEODE CAPITAL MANAGEMENT, LLCTRIM820,062$1.1M
UBS Group AGADD638,699$830.3K
JANE STREET GROUP, LLCDOUBLED607,900$790.3K
STATE STREET CORPTRIM331,395$430.8K
MORGAN STANLEYDOUBLED246,095$319.9K
BNP PARIBAS FINANCIAL MARKETSDOUBLED228,461$297.0K
Bank of New York Mellon CorpTRIM161,689$210.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 67% rate it Buy or better
Strong Buy2Buy6Hold4Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +744%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 15, 2026HC Wainwright & Co.
UPGRADE
UPGRADEBuy
Aug 12, 2026William Blair
DOWNGRADE
DOWNGRADEMarket Perform
Jun 3, 2026Craig-Hallum
DOWNGRADE
DOWNGRADEHold
Jun 1, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Jun 1, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$1.1M
bought · 2 insiders
$0
sold · 0 insiders
−44.4%
vs their $1.44 cost
DateInsiderTypeValue
Jul 14, 2026
Mohindru Mani
Chief Executive Officer
BUY34,364 sh
Jul 14, 2026
PACE GARY W
Director
BUY687,285 sh
Jul 14, 2026
PACE GARY W
Director
BUY$1000.0K
Jul 14, 2026
Mohindru Mani
Chief Executive Officer
BUY$50.0K
Jun 18, 2026
Mohindru Mani
Chief Executive Officer
BUY$29.9K
Jun 18, 2026
PACE GARY W
Director
BUY$36.6K
Jun 11, 2026
PACE GARY W
Director
AWARD40,565 sh
Jun 11, 2026
TANNENBAUM RENEE P
Director
AWARD40,565 sh

Earnings setup

Estimates
Oct 29
reports in 2 days
−$0.13
EPS estimate, this quarter
+23%
estimate change, 90 days
4↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.14–-$0.12+0.0%$86.4K
Next Q-$0.14-$0.20–-$0.09-16.7%$92.9K
Current FY-$0.56-$0.60–-$0.50-1.5%$295.1K
Next FY-$0.54-$0.76–-$0.33+14.8%$320.8K

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 Other
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage
Sep 22, 2026 SEC
Institutional activity in CRDF during Q2 2026 was sharply divided: 15 buyers added $1.6M in new positions (led by Jane…
INST-CLUSTER — Impact 4/10
Sep 14, 2026 SEC
Cardiff Oncology and Nerviano Medical Sciences settled their patent inventorship litigation and amended their 2017…
8-K — Impact 6/10
Aug 11, 2026 SEC
Cardiff Oncology reported Q2 2026 EPS of -$0.18, missing consensus of -$0.16 by 12.5%, with revenue of $104K (below…
PRESS-RELEASE — Impact 6/10
Jul 14, 2026 Insider
Mohindru Mani bought 34,364 shares
Chief Executive Officer
Jul 14, 2026 Insider
PACE GARY W bought 687,285 shares
Director
Jul 14, 2026 Insider
PACE GARY W bought 687,285 shares
Director @ $1.46 ($1000.0K)
Jun 30, 2026 Inst.
BlackRock, Inc. — NEAR_EXIT
972,873 shares ($1.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 29, 2026
Earnings date
CRDF Q3 2026 Earnings After Market Close — 2026-10-29
Recent
Oct 21, 2026
Press release
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1…
Sep 2, 2026
Press release
Cardiff Oncology to Participate in September 2026 Conferences
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1…
Aug 11, 2026
Earnings
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned…
Jul 30, 2026
Earnings date
CRDF Q2 2026 Earnings After Market Close — 2026-07-30
Jul 27, 2026
Earnings date
CRDF Q2 2026 Earnings After Market Close — 2026-07-27

SecBot reports

14 filings · 4 press releases · 6 bullish · 7 bearish · 1 mixed
All CRDF filing & press-release reports (18)